MedPath

A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

Phase 2
Completed
Conditions
Drooling
Registration Number
NCT00515437
Lead Sponsor
Solstice Neurosciences
Brief Summary

To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients

Detailed Description

This is a multi-center, outpatient, double-blind, placebo-controlled, single treatment, sequential dose escalation study designed to evaluate the safety, tolerability and preliminary efficacy of single doses of MYOBLOC versus placebo for the treatment of sialorrhea in Parkinson's disease patients, lasting approximately 20 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria
  • Parkinsons' Disease patients with Sialorrhea for at least 3 months
Exclusion Criteria
  • Patients with non-idiopathic PD parkinsonism
  • Patients previously exposed to botulinum toxins
  • Patients with a history of aspiration pneumonia, moderate/severe choking and/or moderate/severe dysphagia
  • Patients with prior salivary gland surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in Drooling Frequency & Severity Scale (DFSS)at Wk 4 Post-injectionbaseline versus 4 weeks post-injection

9 point scale, 0 = no drooling, 9 = severe drooling

Secondary Outcome Measures
NameTimeMethod
Change in Drooling Frequency and Severity Scale (DFSS) at Wk 12 Post-injectionbaseline vs 12 weeks post injection

9 point scale (0=no drooling, 9=severe drooling)

Change in Unstimulated Salivary Flow Rate at Wk 12 Post-injectionbaseline vs 12 weeks post-injection

saliva collected over 5 minutes and weighed to produce a grams/minute "rate"

Change in Unstimulated Salivary Flow Rate at Wk 4 Post-injectionbaseline vs 4 weeks post-injection

saliva is collected over 5 minutes and weighed to produce a grams/minute "rate"

Trial Locations

Locations (18)

Dr Virgilio Evidente

🇺🇸

Scottsdale, Arizona, United States

Dr. Ronald Ziman

🇺🇸

Northridge, California, United States

Dr. James Sutton

🇺🇸

Oxnard, California, United States

Dr. Olga Klepitskaya

🇺🇸

Denver, Colorado, United States

Dr. Fernando Pagan

🇺🇸

Washington, District of Columbia, United States

Dr Hubert Fernandez

🇺🇸

Gainesville, Florida, United States

Dr. Alan Freeman

🇺🇸

Atlanta, Georgia, United States

Dr. Katie Kompoliti

🇺🇸

Chicago, Illinois, United States

Dr. Robert Rodnitzky

🇺🇸

Iowa City, Iowa, United States

Dr. Stephen Reich

🇺🇸

Baltimore, Maryland, United States

Scroll for more (8 remaining)
Dr Virgilio Evidente
🇺🇸Scottsdale, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.